Phase II study of XELIRI with bevacizumab as second-line therapy for metastatic colorectal cancer -Beyond Progression Disease of capecitabine and bebacizumab -

Phase II study of XELIRI with bevacizumab as second-line therapy for metastatic colorectal cancer -Beyond Progression Disease of capecitabine and bebacizumab - - Phase II study of XELIRI + Bevacizumab as second-line therapy for metastatic colorectal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006877

Enrollment

Registered

2011-12-12

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Interventions

Bevacizumab (7.5mg/kg) and CPT-11(200mg/m2) is administered on day1, and capecitabine (1600mg/m2) is administered from day 1 to day 14

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
response rate	—

Secondary

Measure	Time frame
overall survival, progression-free survival, total survival, safety	—

Countries

Japan

Contacts

Public ContactSoichi Tsutsumi

Gunma University Graduate School Department of General Surgical Science

gundai1geka@gmail.com027-220-8225

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026